The Annual PCVAD Research Award

Finding a Cure for Porcine Circovirus Associated Disease (PCVAD)

Porcine circovirus associated disease (PCVAD) is the relatively new term for a variety of swine diseases causing tremendous economic impact to the global swine industry.

These associated diseases include porcine circovirus type 2 (PCV2) postweaning multisystemic wasting syndrome (PMWS), enteritis and porcine dermatitis and nephropathy syndrome (PDNS). At Boehringer Ingelheim Vetmedica, Inc., we're furthering our commitment to research efforts by funding a new industry-wide research program.

Boehringer Ingelheim will provide three $25,000 ($75,000) awards annually to the winning researchers who submit proposals for PCVAD research in the United States, Canada and Mexico. Candidates include swine researchers, academia, veterinarians and veterinary students and producer organizations.

Submit your completed PCVAD Research proposal packet by July 1, 2008, to:

Boehringer Ingelheim Vetmedica, Inc.
Attn:  Trudy Luther
“PCVAD Research Award Program”
5506 Corporate Drive, Ste. 1600
St. Joseph, MO  64507 USA

For complete proposal packet details visit the instructions page at http://www.PCVADresearch.com/instructions.html.

About Boehringer Ingelheim Vetmedica, Inc.

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.